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Abstract
Background. The recently developed non-invasive high-
intensity focussed ultrasound (HIFU) technique for the de-
struction of parathyroid adenomas could also be of interest
for the treatment of secondary hyperparathyroidism (SHP)
in patients with chronic kidney disease (CKD). We con-
ducted a pilot study using this method.
Methods. Five chronic haemodialysis patients with severe
SHP underwent one to three HIFU treatments, respectively.
They had at least one or two enlarged parathyroid glands,
which were accessible to this technique.
Results. In Patients 1-I and 5-V, serum intact parathyroid
hormone (iPTH) could be successfully reduced in the long
run. In Patient 3-N, serum iPTH decreased dramatically
down to the normal range but increased again subse-
quently. In Patients 2-E and 4-D, transient reductions in
serum iPTH were also obtained but HIFU failed to correct
SHP during follow-up. Serum total calcium and phospho-
rus decreased in four among the ﬁve patients, either tran-
siently or permanently. Serum total alkaline phosphatases
were reduced in four of ﬁve patients. Side effects included
local oedema, transient impairment of vocal cord mobility
and bitonal voice.
Conclusions. HIFU treatment may be of help in controlling
SHP in selected patients with CKD. Further experience is
clearly needed.
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Background
The successful management of severe forms of secondary
hyperparathyroidism (SHP) in patients with chronic kidney
disease (CKD) may prove impossible based on medical ther-
apy alone owing to contraindicationstodrugtreatment,med-
ication intolerance and non-compliance. Even at present,
some of these patients still require surgical parathyroidec-
tomy [1, 2].
Alternative solutions to parathyroid surgery have long
been sought. Percutaneous ethanol injection as a possible
alternative is being successfully used in expert centres in
Japan [3] but not in other countries [4–7].
High-intensity focussed ultrasound (HIFU) is a non-
invasive ablative method based on the generation of extrac-
orporeal ultrasound waves focussed on target tissues. The
energy propagates through the skin without damaging it, up
to the focal point where the temperature increases. HIFU
has been recently shown to be a promising procedure for
patients with primary hyperparathyroidism [8].
The aim of the present pilot study was to test the feasi-
bility, safety and efﬁcacy of the HIFU technique in ﬁve
patients with CKD and severe SHP.
Materials and methods
Five patients with severe SHP agreed to undergo HIFU treatment. Table
1 shows their baseline clinical characteristics. All of them had end-stage
renal disease and were on thrice-weekly stable haemodialysis treatment
for at least 3 months. The serum PTH was >50 pmol/L and on ultra-
sonography (US), there was at least one or two enlarged parathyroid
glands accessible to HIFU treatment, as shown in Table 2, with no
contraindications to this method [8]. Accessibility of the gland to HIFU
treatment was deﬁned as follows: depth of the gland  23 mm from the
posterior border of the gland to skin surface and location >2m ml a t e r -
ally from the oesophagus or the carotid artery and/or >3 mm laterally
from the trachea.
All the patients had high to very high serum intact parathyroid
hormone (iPTH) levels (Figure 1), associated with high serum phospho-
rus and normal to high serum total calcium levels except for Patient 5-V
who had slight hypocalcaemia. All patients were on long-term treatment
with variable doses of oral calcitriol (comprised between 0.125 and
0.5 lg/day) and/or calcium carbonate (comprised between 600 and
4000 mg/day).
The patients were investigated prior to the ﬁrst HIFU treatment, 1 and
7 days, 1, 3, 6, 9 and 12 months post-therapy. In case of persistently
elevated serum iPTH values or lack of parathyroid tumour shrinkage, a
second HIFU treatment was performed at variable time points after the 1-
month visit and follow-up offered as per initial therapy. Two HIFU
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treated per patient.
Biochemical parameters included serum values of iPTH (Elecsys ,
Roche; reference range, 1.6–6.9 pmol/L), total calcium (reference range,
2.12–2.60 mmol/L), phosphorus (reference range, 0.87–1.45 mmol/L) and
total alkaline phosphatases (reference range, 33–110 IU/L).
HIFU treatment was performed as reported recently [8], using the CE-
marked HIFU system (TH-One; THERACLION, Paris, France). In brief,
it included an electronics cabinet, an extracorporeal treatment head, a
cooling unit and an ultrasound imaging scanner. US, including colour
Doppler, was performed using a real-time 8-MHz transducer (Aloka,
Prosound Alpha 7). The parathyroid volume was calculated according
to the formula V ¼ [a 3 b 3 c] 3 p/6, where a, b and c represent
parathyroid gland dimensions. The patients were placed ﬂat on their back,
with the neck hyperextended. Conscious intravenous analgesia was ad-
ministered using a combination of hypnotic agents with opioid and non-
opioid analgesics. During therapy, pulse frequency, blood pressure,
respiration rate and peripheral oxygen tension were monitored, and pa-
tients were asked to indicate any abnormal sensation. All HIFU treat-
ments were performed by one physician (R.K.). The calculation of HIFU
dose was based on treatment site depth. The total energy delivered was a
function of the gland size.
Follow-up US was performed at 1, 3, 6, 9 and 12 months, irrespective
of number of treatments.Alterations in gland size andvascularization were
recorded.
The mobility of the vocal cords was assessed with indirect laryngo-
scopy before and after each HIFU treatment.
The study was approved by the local ethics committee, and written
consent was obtained from each patient.
Results
Patients 1-I and 2-E received three HIFU treatments
(HIFU1, HIFU2 and HIFU3), Patient 3-N received two
HIFU treatments and Patients 4-D and 5-V received only
one HIFU treatment each (see black triangles in Figure 1).
Exposure parameters and treatment times for individual
HIFU treatments are shown in Table 3.
Changes in biochemical parameters and gland volumes
of the patients in response to one or more HIFU treatments
are depicted in Figure 1 and Table 2, respectively. In Pa-
tient 1-I, serum iPTH decreased after HIFU1 and HIFU3,
with transient reascensions after HIFU1 and HIFU2. Over-
all, there was a 60% decrease in iPTH from 112 pmol/L
(baseline) to 45.1 pmol/L 6 months after last HIFU treat-
ment (HIFU3). Serum total calcium decreased markedly
after HIFU2 and HIFU3, and the control of serum phos-
phorus overall improved. The volume of the two treated
glands decreased, respectively, down to 88% (from 0.59 to
0.07 mL) and to 53% (from 2.12 to 1.00 mL) 12 months
after the last HIFU treatment (HIFU3).
In Patient 2-E, HIFU1 and HIFU3 also led to a decrease
in serum iPTH but subsequently iPTH levels rose again,
with the ﬁnal value being higher than baseline (Figure 1).
Serum total calcium decreased markedly after HIFU1 and
HIFU3 to values slightly below normal. However, the con-
trol of serum phosphorus remained relatively poor. The
volume of the ﬁrst parathyroid gland treated decreased to
~60% after HIFU1. Due to marked shrinkage of this ﬁrst
gland, it was decided to treat the other visible gland as well.
In contrast, the volume of the second gland treated re-
mained unchanged after HIFU2 but decreased after HIFU3,
down to 21% from baseline.
In Patient 3-N, serum iPTH exhibited a maximum de-
crease from 59 to 38 pmol/L after HIFU1 and from 69
Table 2. Parathyroid glands location and volumes, number of HIFU treatments (per gland and per patient) and evolution of gland volumes compared to
baseline
a
Patient
ID
Number of
glands at
ultrasound
Gland
location
HIFU
treatments
Baseline gland
volume (mL)
6m o
post-last
HIFU (mL)
12 mo
post-last
HIFU (mL)
Change of
volume at last
follow-up (%)
1-I 2 RI HIFU1 1 HIFU2 0.59 0.13 0.07  88.1
LI HIFU3 2.12 0.66 1.00  52.8
2-E 2 LI HIFU1 1.05 0.42 n.a.  60.0
RI HIFU2 1 HIFU3 0.95 0.75 n.a.  21.1
3-N 1 LS HIFU1 1 HIFU2 1.24 0.83 0.73  41.1
4-D 1 RI HIFU1 0.91 0.25 0.54  40.6
5-V 2 RI HIFU1 0.87 0.05 n.a.  94.3
LI No treatment 0.28 0.25 n.a. n.a.
aRI, right inferior; LI, left inferior; LS, left superior; mo, month; HIFU1, ﬁrst HIFU treatment; HIFU2, second HIFU treatment; HIFU3, third HIFU
treatment; n.a., not available.
Table 1. Baseline demographic characteristics
Patient
ID Age (years) Gender
Underlying
nephropathy
causes
CKD-associated
complications
Haemodialysis
vintage (years)
1-I 56 M Membranous glomerulonephritis Soft tissue calciﬁcations, anaemia 7
2-E 55 F ADPKD
a and chronic pyelonephritis Hypertension, anaemia 5
3-N 37 M Obstructive uropathy (Marion’s disease) Multiple fractures (femoral neck,
patella and wrist)
19
4-D 35 M ADPKD None 2
5-V 42 M Interstitial nephritis Hypertension, anaemia 28
aADPKD, adult-dominant polycystic kidney disease.
Ultrasound ablation of hyperplastic parathyroid glands 77Fig. 1. Serum biochemistry of all patients, separated in two groups: Group 1, Patients 1-I, 2-E and 3-N who received two or three HIFU treatments;
Group 2, Patients 4-D and 5-V who received only one HIFU treatment, with a total follow-up till 90 weeks. (A–D) Graphs show changes in serum intact
parathyroid hormone (A1 and A2), total calcium (B1 and B2), phosphorus (C1 and C2) and total alkaline phosphatase (D1 and D2) levels for the two
groups after each HIFU treatment (black triangles).
78 R.D. Kovatcheva et al.down to 4 pmol/L after HIFU2. Serum total calcium, phos-
phorus and total alkaline phosphatases remained essentially
unchanged. A marked decrease of gland volume has been
observed 3 months after last HIFU treatment. Thereafter,
the volume remained constant.
In Patient 4-D, serum iPTH decreased from 72 to 56
pmol/L, and in Patient 5-V from 146 to 81 pmol/L after
HIFU1. These two latter patients had no further HIFU
treatments due to vocal cord mobility impairment for pa-
tient 4-D and road accident for patient 5-V. For both pa-
tients, a marked decrease in the volume of treated glands
was observed. The volume reduction was 72 and 94%
from baseline at 6 months post-HIFU1, however, with a
subsequent reascension in Patient 4-D. In summary, serum
total calcium, phosphorus levels and serum alkaline phos-
phatases decreased in four among the ﬁve patients, either
transiently or permanently, but remained unchanged in
Patient 3-N.
HIFU-related adverse events, all transient, consisted of
mild subcutaneous oedema in three patients (for some
days), of prolonged vocal cord mobility impairment in
two patients (for 9 and 11 months, respectively), of pro-
longed bitonal voice in one patient (for 9 months) and of
difﬁculty in swallowing water in one patient (for 3 weeks).
Discussion
Surgical removal of the parathyroid glands remains the
ultimate treatment of the most severe forms of SHP in
patients with CKD who fail to respond to or comply with
medical treatment, including dietary phosphate restriction
and optimal dialysis management in those with end-stage
kidney disease or who do not tolerate it because of major
adverse events [9]. This has also been recommended in the
recent KDIGO guideline on the CKD-related mineral and
bone disorder (CKD–MBD) [10].
Since most patients clearly prefer minimally invasive or
non-invasive therapies, it appears legitimate to seek
non-surgical methods for the physical destruction of hyper-
plastic parathyroid glands. The HIFU technique could be
such an alternative option, as recently shown by us in pa-
tients with primary parathyroid adenomas [8]. HIFU might
also be useful in CKD patients with SHP. However, the
problem in such patients is that generally parathyroid hy-
perplasia is not limited to one gland, although the degree of
hyperplasia may be highly variable from one gland to the
other. We reasoned that in patients having only one or two
greatly enlarged parathyroid glands, HIFU could be helpful
in managing SHP.
The present pilot study in ﬁve cases with SHP represents
the ﬁrst experience with the HIFU technique in chronic
haemodialysis patients. Our report illustrates the potential
beneﬁts, but also the limitations, of this method in the set-
ting of CKD. A marked decrease of serum iPTH could be
achieved in three patients after one or more (up to three)
HIFU treatments applied to one or two accessible hyper-
plastic glands, down to the PTH range recommended by the
recent KDIGO CKD–MBD guideline or even below [10].
Concomitantly, the control of serum calcium and phospho-
rus also was improved, although only transiently in most
instances. In the long run, however, HIFU treatment was
successful in only two patients. The main reasons for un-
successful long-term PTH control in three of ﬁve patients
probably included an extreme severity of SHP linked to the
presence of remaining, undestroyed hyperplastic parathy-
roid glands, the impossibility to perform repeat HIFU treat-
ments in some patients owing to side effects and the
probable progression of parathyroid hyperplasia in non-
treated glands. Of note, in patients with extremely severe
SHP, the surgical removal of only one or two glands would
also not be sufﬁcient to correct parathyroid overfunction.
The presence of diffuse major parathyroid hyperplasia in
three or more glands clearly is a limitation for the success
of the HIFU method. The accessibility of the targeted gland
for this type of therapy is another limitation. In any case,
HIFU can only be considered, if proven effective by further
study, as an adjunct therapy in patients with CKD and SHP
since the primary causes of PTH oversecretion are not af-
fected by this type of treatment. It could allow uraemic
patients to respond more effectively to established medical
therapy or reduce drug needs in that HIFU might greatly
reduce the hyperplastic gland mass in some of them and
thereby create a more favourable PTH secretory context.
Clearly, even the entire destruction of one or two hyper-
plastic parathyroid glands in patients with CKD does not
protect against progressive hyperplasia of the remaining
glands if not accompanied by adequate medical treatment.
Side effects of HIFU treatment also have to be consid-
ered. Like with surgery, recurrent nerve palsy may occur
but this complication should only be transient, as observed
in two patients. Local subcutaneous oedema of short dura-
tion and without clinical signiﬁcance was observed in three
patients. There was no clear-cut association between the
energy delivered to the glands and the occurrence of oe-
dema or nerve palsy. The incidence of local side effects of
Table 3. Exposure parameters for each parathyroid gland to individual
HIFU treatments
a
Average
depth (mm)
Total
exposure
time (min)
Total HIFU
delivered
energy (kJ)
Mean HIFU
power (W)
Patient 1-I
HIFU1, RI PT 19.0 2.2 4.7 6.5
HIFU2, RI PT 16.0 2.2 5.1 3.0
HIFU3, LI PT 21.4 7.0 24.0 5.5
Patient 2-E
HIFU1, LI PT 20.0 3.9 20.6 5.2
HIFU2, RI PT 18.0 8.9 19.9 7.9
HIFU3, RI PT 19.7 4.0 22.4 5.4
Patient 3-N
HIFU1, LS PT 23.8 4.0 7.8 2.6
HIFU2, LS PT 22.6 9.0 15.3 5.0
Patient 4-D
HIFU1, RI PT 21.8 3.1 8.6 3.7
Patient 5-V
HIFU1, RI PT 19.7 2.1 11.0 5.9
aThe HIFU frequency was 3 MHz for all treatments. Total exposure time
(duration of HIFU pulses per patient) and HIFU delivered energy [total
delivered energy to parathyroid glands (PT) taking into account tissue
attenuation] depend on treated PT volume. Due to pauses between pulses
(cooling time, repositioning and pauses for other reasons), the mean power
applied is quite low. RI, right inferior; LI, left inferior; LS, left superior.
Ultrasound ablation of hyperplastic parathyroid glands 79HIFU treatment should decrease with improved selection
concerning the size and location of parathyroid glands,
possibly earlier treatment initiation and more extended ex-
perience with the maximal amount of energy needed for the
destruction of the targeted parathyroid tissue.
The HIFU technique may be suitable for CKD patients
with various degrees of SHP and hyperplastic parathyroid
glands accessible to this technique, in those in whom
medical treatment is unsuccessful, in patients in whom
cinacalcet treatment is not possible or contraindicated
and in those who refuse or have contraindications to para-
thyroid surgery.
In conclusion, the HIFU technique may enable a marked
reduction of SHP in those uraemic patients in whom PTH
oversecretion mainly stems from one or two HIFU acces-
sible hyperplastic glands. In these patients, it could repre-
sent a non-surgical alternative to parathyroidectomy. More
importantly, it might become a valuable adjunct therapy to
medical treatment at earlier stages of SHP.
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